After two months, Novo Nordisk and HIMS part ways
Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
Widespread access to Semaglutide (Ozempic, Wegovy, Rybelsus) and Tirzepatide (Mounjaro, Zepbound) via compounding made Novo Nordisk and HIMS enemies.
While consumers were happy to be able to get GLP1 Receptor Agonists at much lower cost, HIMS, other compounding pharmacies and companies ties to them were eating directly into companies like Novo Nordisk and Eli Lilly's profits.
Eli Lilly sued compounding pharmacies:
Eli Lilly suing GLP1 compounders & related companies
Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.
GLP1.Guide Staff
While initially antagonistic, Novo Nordisk, which was facing a somewhat more intense dip in demand due to the greater effectiveness of Tirzepatide actually went another way – they partnered with HIMS just two months ago:
